Sanofi licenses hard-to-make asthma drug to Acton – FiercePharma Manufacturing

Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing
Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006.
Acton Pharmaceuticals, Inc. Announces License Agreement WithPharmaceutical Online (press release)

all 2 news articles »

View full post on asthma – Google News